Cool post Vinny.Understand the dissapoinment in the SP...yes it...

Cool post Vinny.

Understand the dissapoinment in the SP...yes it hurts BUT for all holders, Just to reiterate the upcoming News Flow (per 26 Feb 14 presentation):

Key deliverables in 2014
– Regulatory submissions in major markets for GVHD product approvals
– Commencement of Phase 3 trial in intervertebral disc disease
– Continued recruitment of Phase 3 trials in congestive heart failure, Crohn’s
disease, and expanded cord blood for bone marrow transplantation
– Continued recruitment and results from Phase 2 trials of diabetic nephropathy,
AMI, RA
– Commercial scale manufacturing and bioprocessing in preparation for
commercial launches
– Evolving strategy for early product approvals in Japan


The last one is very interesting ..as this seems to me over and above the JRC Pharma GVHD product approvals which is listed as the 1st one under News Flow.

Anglelus - dont worry about what the shorters say.
TEVA commenced CHF P3 on the back of the Facts/amazing P values/ expert Medical advice/1700 patients FDA approved..this is real and on par with the DDD very impressive results.

Above is my perspective only so always good to take alternative views....AND most importantly DYOR.